Dong-A announces positive results for Zydena in hypertensive and diabetic patients

Published: 2007-11-29 06:57:00

Updated: 2007-11-29 06:57:00

Dong-A Pharmaceutical says it has successfully completed its 10-month clinical study for 135 hypertensive patients and 156 diabetic patients in 13 local university hospitals, including Seoul National University Hospital and Korea University Anam Hospital, for Zydena (udenafil), its new long acting (12 hour half-life) oral phosphodiesterase type 5 (PDE5) inhibitor for erectile dysfunction (ED).
...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.